YILIMART - MSC-Brew GMP Medium

MSC-Brew GMP Medium is an optimized and standardized medium for the generation and expansion of mesenchymal stem cells (MSCs) from human bone marrow (BM) or other tissue sources. The formulation of MSC-Brew GMP Medium is designed to efficiently support the expansion of MSCs

in vitro

while maintaining their differentiation potential. The medium is xeno- and serum-free and is manufactured under strictly controlled conditions using ingredients of the highest quality. MSC-Brew GMP Medium offers consistent lot-to-lot performance and optimal conditions for the cultivation of MSCs.

Disclaimer

MACS GMP Products are for research use and

ex vivo

cell culture processing only, and are not intended for human

in vivo

applications. For regulatory status in the USA, please contact your local representative.

Background information

MSC-Brew GMP Medium is based on the formulation of StemMACS MSC Expansion Media Kit XF (#130-104-182) thus enabling seamless translation from research to clinical applications.

Serum-free and xeno-free formulation
Manufactured under strictly controlled conditions
Consistent lot-to-lot performance
Quality control: functionality test on every batch
500 mL or 2000 mL bags – without phenol red

Applications

The MSC-Brew GMP Medium is an optimized and standardized xeno- and serum-free medium for the reproducible and reliable isolation and expansion of MSCs from human bone marrow and other human tissues, such as adipose tissue and umbilical cord.

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Figure 1
View details

Figure 1

The differentiation potential of MSCs was assessed for adipocytes (A), chondrocytes (B), and osteoblasts (C). MSCs were cultivated in StemMACS AdipoDiff Medium for18 days and adipocyte differentiation was analyzed using a lipid-staining dye (red) to demonstrate lipid accumulation. Nuclei were detected with Dapi (blue).

After 26 days of culture in StemMACS ChondroDiff Medium, chondrocyte differentiation was analyzed using an anti-aggrecan antibody (red) for detection of proteoglycan. Nuclei were detected with Dapi (blue). After 10 days of culture in StemMACS OsteoDiff Medium, osteoblast differentiation was analyzed by detection of alkaline phosphatase activity.

The differentiation potential of MSCs was assessed for adipocytes (A), chondrocytes (B), and osteoblasts (C). MSCs were cultivated in StemMACS AdipoDiff Medium for18 days and adipocyte differentiation was analyzed using a lipid-staining dye (red) to demonstrate lipid accumulation. Nuclei were detected with Dapi (blue).

After 26 days of culture in StemMACS ChondroDiff Medium, chondrocyte differentiation was analyzed using an anti-aggrecan antibody (red) for detection of proteoglycan. Nuclei were detected with Dapi (blue). After 10 days of culture in StemMACS OsteoDiff Medium, osteoblast differentiation was analyzed by detection of alkaline phosphatase activity.
Figure 2
View details

Figure 2

MSC-Brew GMP Medium supports expansion of MSCs derived from human bone marrow, human adipose tissue, and human umbilical cord. Human bone marrow–derived (BM-MSC), adipose tissue–derived (AT-MSC), and umbilical cord–derived MSCs (UC-MSC) were cultured in MSC-Brew GMP Medium. MSCs were plated at 3,000 cells/cm
²
and cell count was assessed over three passages.

The growth curve was calculated by combining the final viable cell count at each passage per day with the initial seeded viable cell count. Each passage was harvested at 80% confluence.

MSC-Brew GMP Medium supports expansion of MSCs derived from human bone marrow, human adipose tissue, and human umbilical cord. Human bone marrow–derived (BM-MSC), adipose tissue–derived (AT-MSC), and umbilical cord–derived MSCs (UC-MSC) were cultured in MSC-Brew GMP Medium. MSCs were plated at 3,000 cells/cm
²
and cell count was assessed over three passages.

The growth curve was calculated by combining the final viable cell count at each passage per day with the initial seeded viable cell count. Each passage was harvested at 80% confluence.
Figure 3
View details

Figure 3

Comparison of MSC-Brew GMP Medium to other media compositions used for cell manufacturing reveals advantageous growth kinetics when MSC-Brew GMP Medium is used. Clinically relevant cell numbers are reached within a shorter time frame (14 days faster), which in turn results in less media consumption. Overall media consumption can be reduced up to 70%.

Comparison of MSC-Brew GMP Medium to other media compositions used for cell manufacturing reveals advantageous growth kinetics when MSC-Brew GMP Medium is used. Clinically relevant cell numbers are reached within a shorter time frame (14 days faster), which in turn results in less media consumption. Overall media consumption can be reduced up to 70%.